Cells are the basic building blocks of all living things. So, in order to treat or cure almost any disease or condition – including cancer – you first need to have a fundamental understanding of cell biology.. While researchers have a pretty good understanding of what each component of a cell does, there are still things we don’t know about them – including the role that some RNAs molecules play in a cell. Finding the answer to this may be key in developing further cancer treatments, which is what our research has sought to uncover.

Nowadays, any discussion around healthcare for your employees will inevitably center around Covid. At a time when the pandemic and its challenges are still making headlines as outbreaks, infection rates and vaccines flood every news bulletin, it’s easy to overlook the impact on other areas of healthcare. Many of these involve complex or life-threatening illnesses, such as cancer. Global Benefits Vision recently spoke to Further Group CEO Frank Ahedo about the impact that Covid is having on the treatment of serious medical conditions, and how this changing landscape will affect the way employees have access to treatment.

Two US researchers recently sparked controversy with their work on the role of “luck” in cancer. Their latest article was published in the March issue of the prestigious journal Science. The researchers, Christian Tomasetti and Bert Vogelstein of John Hopkins University in Baltimore, showed that the disease is less dependent on hereditary (a genetic predisposition) and environmental risks (such as smoking, or asbestos exposure) than on random mutations (such as DNA replication errors) arising spontaneously in cells as they divide and reproduce over the course of our lifetimes.

The emergence of new, more expensive, cancer drug therapies that help the immune system attack tumors is expected to increase cancer drug spending to over $150 billion by 2020 according to a global oncology report released by IMS Health Holdings. This represents an annual global growth rate for oncology drug spending of 7.5% to 10.5% through 2020, up from last year’s IMS forecast of 6% to 8% growth. The

Despite the obvious benefits of exercise, cancer patients are avoiding exercise. According to MacMillan Cancer Support (MCS), which launched a study conducted by YouGov Research, many patients avoid exercise for varying reasons, the top three of which are: worrying about being able to find a toilet (36%), feeling uncomfortable getting active in public (31%) and feeling uncomfortable in active wear or bathing suit (24%). Group exercise therapy delivers benefits

The spread of cancer, or metastasis, has historically been one of the most significant hurdles in the treatment of the deadly disease. In metastasis, when cancer cells break away from a tumor, they spread throughout the body, infecting other organs and vital systems. The question of how these cells survive is closer to being answered, however, thanks to research being performed by Barts Cancer Institute at Queen Mary University

As a response to growing concerns over the high cost of cancer care, the Northeast Business Group on Health (NEBGH) Solutions Center, over the course of two 2015 workshops, mounted a study that surveyed 19 self-insured employers representing 1.2 million employees, as well as physicians, oncology experts, employer benefits professionals, executives from health plans, hospitals, consulting organizations, cancer associations, and suppliers of healthcare-related services. The purpose of the study